- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00094965
Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function (FOLFOX4)
Phase II Trial of Oxaliplatin in Combination With Bolus/Infusional 5FU/LV (FOLFOX4) in Patients With Advanced Gastrointestinal (GI) Cancers With Varying Degrees of Renal Impairment
This trial is a phase II study in patients with advanced gastrointestinal (GI) malignancies who will be assigned to one of 4 cohorts (normal, mild, moderate and several renal dysfunction) based on their baseline measured creatinine clearance then treated with FOLFOX4.
Standard bone marrow and liver function inclusion and exclusion criteria must be met prior to study treatment. FOLFOX4 in the study is given every 2 weeks (1 cycle = 2 weeks) for up to 12 cycles unless there are treatment delays to allow for recovery from toxic effects. Dose modifications are included for protocol specified toxicities. After 12 treatment cycles on study, patients who are having a beneficial disease response may continue to have oxaliplatin supplied off study to continue the treatment regimen until disease progression, prohibitive toxicity or death.
Oxaliplatin pharmacokinetic studies (plasma and urine) are planned during cycles 1 and 2 on each patient. Creatinine clearance will be assessed every 2 cycles and disease status will be assessed every 3 cycles of treatment during the study.
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232-6307
- Vanderbilt-Ingram Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed locally advanced or metastatic gastrointestinal (GI) malignancy;
- Patients may have measurable or non-measurable disease;
- Prior chemotherapy, radiation therapy, hormonal therapy and immunotherapy are allowed, with the exception that patients cannot have had prior treatment with oxaliplatin, cisplatin or other nephrotoxic anticancer agent;
- Patients must have had no chemotherapy or radiotherapy within 4 weeks (28 days) prior to entering the study;
- Age 18 or older;
- Karnofsky performance status of 70% or greater for patients with normal or mildly abnormal renal function and 50% or greater for patients with moderately or severely abnormal renal function;
- Life expectancy of at least 3 months;
- Adequate bone marrow function (WBC > or = 3000 cells/mm3, ANC > or = 1500 cells/mm3, platelets > or = 100,000 cells/mm3);
- Adequate liver function (total bilirubin < or =1.5 times the institutional upper limit of normal (IULN), AST (SGOT)/ALT (SGPT) < or = 2 times the IULN, unless liver metastases are present and documented at baseline by CT or MRI scan (< or = 5 times IULN in that case), alkaline phosphatase < or = 2 times the IULN, unless liver metastases are present and documented at baseline by CT or MRI scan (< or = 5 times IULN in that case));
- Patients may have a Grade 1 neurotoxicity at study entry. Absence of deep tendon reflexes as a sole neurological abnormality does not render the patient ineligible;
- If female, not pregnant or lactating at inclusion. Documentation of a negative serum HCG pregnancy test for women of child bearing potential is required at inclusion;
- Women of child bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and for 6 months after discontinuation of study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately;
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients with active hydronephrosis (patients with a functioning ureteral stent are allowed on study);
- Patients who have had chemotherapy or radiotherapy within 4 weeks (28 days) prior to entering the study;
- Patients who have had a major surgery within 4 weeks (28 days) prior to entering the study;
- Patients who had prior therapy with oxaliplatin, cisplatin or other nephrotoxic anticancer agent;
- History of allergy to platinum compounds;
- Patients undergoing therapy with other investigational agents. Patients who received any investigational drug must have discontinued the investigational drug 30 days or more before beginning treatment on this study;
- Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency;
- Patients who have had a history of cardiac toxicities while on 5FU/LV therapy or myocardial infarction < or = 6 months prior to study entry;
- Patients with known brain metastases because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurological and other toxicities;
- Patients with interstitial pneumonia or extensive and symptomatic fibrosis of the lungs;
- Patients with uncontrolled intercurrent illness (high blood pressure, unstable angina pectoris, symptomatic congestive heart failure (NYHA III or IV), severe cardiac arrhythmia, uncontrolled diabetes or active infection);
- Pregnant or lactating women.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: 1
|
oxaliplatin in combination with FOLFOX4
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Adverse events.
Tidsramme: 12 Cycles
|
12 Cycles
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Pharmacokinetics.
Tidsramme: 2 Cycles
|
2 Cycles
|
Tumor evaluations for response or progressive disease.
Tidsramme: 12 Cycles
|
12 Cycles
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- POP5347
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Mage-tarmkreft
-
AstraZenecaJohnson & Johnson K.K. Medical CompanyFullførtGastrointestinal endoskopi | Gastrointestinal polypektomiJapan
-
University of AarhusMotilis,SwitzerlandFullførtMagetømming | Gastrointestinal motilitet | Total Gastrointestinal Transit Time | Segmentell transporttidDanmark
-
Massachusetts General HospitalPåmelding etter invitasjonGastrointestinal dysfunksjon | Gastrointestinal sykdomForente stater
-
Hospital Universitari Vall d'Hebron Research InstituteInstituto de Salud Carlos IIIRekrutteringGastrointestinal motilitetsforstyrrelseSpania
-
Coconut Goodness Food Products Inc.Aktiv, ikke rekrutterendeGastrointestinal dysfunksjonForente stater
-
Nutricia ResearchFullførtGastrointestinal toleransePolen
-
James J. Peters Veterans Affairs Medical CenterTilbaketrukketGastrointestinal dysfunksjonForente stater
-
Cedars-Sinai Medical CenterUniversity of Michigan; NestléFullført
-
Baylor College of MedicineAlliance for Academic Internal MedicineFullførtEndoskopi, GastrointestinalForente stater
-
Abbott NutritionFullført
Kliniske studier på Oxaliplatin (SR96669)
-
SanofiFullførtKolon neoplasmerFrankrike, Polen, Tyskland, Italia, Nederland, Portugal, Spania, Sverige, Sveits, Singapore, Belgia, Danmark, Ungarn, Israel, Norge, Storbritannia, Australia, Østerrike, Hellas
-
SanofiFullført
-
Yixing People's HospitalRekruttering
-
Xiangya Hospital of Central South UniversityUkjentNeoplasma Metastase | Nevroendokrine svulster | LeverKina
-
Fudan UniversityRekrutteringLokalt avansert tykktarmskreftKina
-
Soonchunhyang University HospitalUkjentMagekreft | Eldre | Oksaliplatin | S-1 | Første linje
-
SanofiTilbaketrukket
-
SanofiFullførtNeoplasmer i magenFrankrike, Den russiske føderasjonen, Portugal, Spania, Forente stater, Tyrkia, Belgia, Ungarn, Italia, Storbritannia, Tyskland, Sveits
-
Central European Cooperative Oncology GroupFullførtTykktarmskreftIsrael, Østerrike, Kroatia, Hellas, Serbia, Bosnia og Herzegovina, Bulgaria, Estland, Ungarn, Latvia, Romania, Slovakia, Slovenia